Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Assets: 2022-2024

Historic Other Non-Current Assets for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $632,000.

  • Corvus Pharmaceuticals' Other Non-Current Assets rose 238.10% to $852,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $852,000, marking a year-over-year increase of 238.10%. This contributed to the annual value of $632,000 for FY2024, which is 610.11% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Other Non-Current Assets of $632,000 as of FY2024, which was up 610.11% from $89,000 recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Other Non-Current Assets peaked at $632,000 during FY2024, and registered a low of $89,000 during FY2023.
  • For the 3-year period, Corvus Pharmaceuticals' Other Non-Current Assets averaged around $283,333, with its median value being $129,000 (2022).
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Other Non-Current Assets plummeted by 31.01% in 2023, and later soared by 610.11% in 2024.
  • Corvus Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $129,000 in 2022, then plummeted by 31.01% to $89,000 in 2023, then skyrocketed by 610.11% to $632,000 in 2024.